Header image

Embecta Education Hub: Sharpening Awareness: Addressing Needlestick Injuries

Friday, August 23, 2024
1:10 PM - 1:55 PM

Details

Learning Objectives: 1. Understand the Incidence and burden of needle stick injuries (NSI) 2. Discuss the common causes, concerns and approaches to address issues with NSI 3. Enhance safety through best practices and benefits of Safety-Engineered Needle Devices (SENDs) Needlestick injuries (NSIs) pose a significant hazard for healthcare workers globally.1 The Centers for Disease Control and Prevention (CDC) reports 385,000 NSIs among healthcare professionals in the United States (US) annually.2 NSIs can be experienced by any healthcare professional who uses needles and/or any sharp objects including individuals from a range of occupations working in hospitals, aged and mental healthcare facilities and other healthcare services such as social and community services.3 Based on a report* at least 18,000 Australian healthcare professionals suffer a NSI every year. These injuries are largely preventable.4 In addition to the increased risk of infections, NSIs are also a primary source of emotional distress and job burnout for HCWs and patients.1,5 The majority of NSI-associated costs are generally borne by the healthcare organisation where the injury occurred.4 Direct costs include testing the source and exposed HCW, in addition to post-exposure medical visits and treatment (prophylaxis). Indirect costs include lost productivity due to time off from work, litigations, and exposure consequences such as emotional distress and anxiety.1 The incidence of NSIs among HCWs in the APAC region has been reported to be associated with age (shorter length of experience), history of related training/education, failure to observe precautions, and number of shifts per month.1 Education on optimal injection methods, safety-engineered needle devices, sharps disposal, adequate staff-to-patient ratios, and interactive learning and skill validation for new healthcare workers are needed to prevent NSIs.1 The CDC guidelines also emphasize the importance of a “safety culture” while recognizing the need for institution-specific occupational health and safety programs.1 This session emphasizes on current approaches, key strategies/recommendations to address the issues associated with NSIs and the benefits of introducing Safety-Engineered Needle Devices (SENDs) in health care settings, including long-term care facilities, nursing homes, and home care settings where people may require assisted insulin injections. *Based on the 2435 parenteral exposures sustained by staff reported in 2005 from 170 Australian hospitals.


Speaker

Agenda Item Image
Dr Shailendra Bajpai
Medical And Public Affairs Director, Asia
Embecta

Sharpening Awareness: Addressing Needlestick Injuries

1:10 PM - 1:55 PM

Biography

Dr. Shailendra Bajpai is a specialist physician trained in Internal Medicine, Diabetes & Endocrinology with over 30 yrs. of experience in clinical practice, public health, biopharmaceuticals and health technology. He is currently the Medical & Public Affairs Director- Asia for embecta (formerly Becton Dickinson Diabetes Care), based in Singapore. He had his medical education and training at renowned academic institutions and international COEs including the All India Institute of Medical Science, International Diabetes Center, Minneapolis, USA, by the American Diabetes Association and by Vienna School of Clinical Research. Dr. Bajpai is passionate about improving the lives of people with Diabetes and their loved ones. He has established several PPPs in developing countries, including Asia with the objective of enhancing the knowledge & skills of the providers, creating advocacy, improving access, and uplifting the standards of care through multi-stakeholder healthcare ecosystems. Dr. Bajpai has been involved as a clinical research physician and medical advisor in the development programs of Air Insulin, incretin mimetics, certolizumab pegol, rotigotine and with the launch of first in class incretin mimetic- exenatide (Byetta), lixisenatide (Lyxumia), insulin analogues (Insulin Lispro, Insulin IGlar U300), GLP-1 agonists & Insulin combinations (Soliqua) as well as several other drugs in cardio-metabolic and neuropsychiatry therapeutic areas. He has also worked on Digital Health and Medical technology solutions in Diabetes and CV- metabolic space. He has authored several original research articles in peer reviewed international scientific journals and is on the editorial board of journals of repute. He is an SME, a speaker & author on health and wellness topics for diverse audiences including public, patients, providers and policy makers. He has founded and works closely with Non-profits in education, health and wellness and in the social impact sector. He has recently been featured in the book ‘A dose of inspiration’ - 100 purpose stories from pharma leaders . His work includes education on living well with diabetes, management of Diabetes, & health and wellbeing with a holistic perspective. He firmly believes that community and peer support, patient empowerment, awareness, education and advocacy with the proper use of technology can move the needle for prevention, diagnosis, and better management of Diabetes and other chronic diseases. He contributes to the integrated care, health tech & med-tech ecosystem as an SME mentor. He is also a meditation and mindfulness practitioner and coach.
loading